title: Anti-vascular endothelial growth factor therapy-induced glioma invasion is associated with accumulation of Tie2-expressing monocytes.
abstract: The addition of anti-angiogenic therapy to the few treatments available to patients with malignant gliomas was based on the fact that these tumors are highly vascularized and on encouraging results from preclinical and clinical studies. However, tumors that initially respond to this therapy invariably recur with the acquisition of a highly aggressive and invasive phenotype. Although several myeloid populations have been associated to this pattern of recurrence, a specific targetable population has not been yet identified. Here, we present evidence for the accumulation of Tie2-expressing monocytes/macrophages (TEMs) at the tumor/normal brain interface of mice treated with anti-VEGF therapies in regions with heightened tumoral invasion. Furthermore, we describe the presence of TEMs in malignant glioma surgical specimens that recurred after bevacizumab treatment. Our studies showed that TEMs enhanced the invasive properties of glioma cells and secreted high levels of gelatinase enzymatic proteins. Accordingly, Tie2⁺MMP9⁺ monocytic cells were consistently detected in the invasive tumor edge upon anti-VEGF therapies. Our results suggest the presence of a specific myeloid/monocytic subpopulation that plays a pivotal role in the mechanism of escape of malignant gliomas from anti-VEGF therapies and therefore constitutes a new cellular target for combination therapies in patients selected for anti-angiogenesis treatment.
authors.affiliation: Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
authors.forename: Konrad
authors.initials: K
authors.lastname: Gabrusiewicz
authors.forename: Dan
authors.initials: D
authors.lastname: Liu
authors.forename: Nahir
authors.initials: N
authors.lastname: Cortes-Santiago
authors.forename: Mohammad B
authors.initials: MB
authors.lastname: Hossain
authors.forename: Charles A
authors.initials: CA
authors.lastname: Conrad
authors.forename: Kenneth D
authors.initials: KD
authors.lastname: Aldape
authors.forename: Gregory N
authors.initials: GN
authors.lastname: Fuller
authors.forename: Frank C
authors.initials: FC
authors.lastname: Marini
authors.forename: Marta M
authors.initials: MM
authors.lastname: Alonso
authors.forename: Miguel Angel
authors.initials: MA
authors.lastname: Idoate
authors.forename: Mark R
authors.initials: MR
authors.lastname: Gilbert
authors.forename: Juan
authors.initials: J
authors.lastname: Fueyo
authors.forename: Candelaria
authors.initials: C
authors.lastname: Gomez-Manzano
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000818:Animals; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D000068258:Bevacizumab; D001932:Brain Neoplasms / Q000188:drug therapy / Q000473:pathology*; D019008:Drug Resistance, Neoplasm / Q000502:physiology*; D004797:Enzyme-Linked Immunosorbent Assay; D005434:Flow Cytometry; D005455:Fluorescent Antibody Technique; D005910:Glioma / Q000188:drug therapy / Q000473:pathology*; D006801:Humans; D007150:Immunohistochemistry; D020780:Matrix Metalloproteinase 9 / Q000096:biosynthesis; D051379:Mice; D008819:Mice, Nude; D018613:Microscopy, Confocal; D009000:Monocytes / Q000378:metabolism / Q000473:pathology*; D009361:Neoplasm Invasiveness / Q000473:pathology; D009364:Neoplasm Recurrence, Local / Q000473:pathology*; D042787:Receptor, TIE-2 / Q000378:metabolism; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D023041:Xenograft Model Antitumor Assays
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab; D042787:Receptor, TIE-2; D020780:Matrix Metalloproteinase 9